Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 61

1.

Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

Holstein SA, Ye JC, Howard A, Bhutani M, Gormley N, Hahn T, Hillengass J, Krishnan A, Landgren CO, Munshi NC, Oliva S, Owen RG, Pasquini MC, Puig N, Weinhold N, Weisel K, McCarthy PL.

Biol Blood Marrow Transplant. 2019 Mar;25(3):e89-e97. doi: 10.1016/j.bbmt.2018.11.001. Epub 2018 Nov 5.

PMID:
30408566
2.

Immunotherapy Combinations in Multiple Myeloma - Known Unknowns.

Gormley NJ, Pazdur R.

N Engl J Med. 2018 Nov 8;379(19):1791-1795. doi: 10.1056/NEJMp1803602. No abstract available.

PMID:
30403935
3.

Bead-linked transposomes enable a normalization-free workflow for NGS library preparation.

Bruinsma S, Burgess J, Schlingman D, Czyz A, Morrell N, Ballenger C, Meinholz H, Brady L, Khanna A, Freeberg L, Jackson RG, Mathonet P, Verity SC, Slatter AF, Golshani R, Grunenwald H, Schroth GP, Gormley NA.

BMC Genomics. 2018 Oct 1;19(1):722. doi: 10.1186/s12864-018-5096-9.

4.

Cost-Benefit Analysis of Transitional Care in Neurosurgery.

Liu J, Gormley N, Dasenbrock HH, Aglio LS, Smith TR, Gormley WB, Robertson FC.

Neurosurgery. 2019 Nov 1;85(5):672-679. doi: 10.1093/neuros/nyy424.

PMID:
30272201
5.

Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications.

Pulte ED, Nie L, Gormley N, Goldberg KB, McKee A, Farrell A, Pazdur R.

Blood Adv. 2018 Jan 23;2(2):116-119. doi: 10.1182/bloodadvances.2017010512. No abstract available.

6.

FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.

Bhatnagar V, Gormley NJ, Luo L, Shen YL, Sridhara R, Subramaniam S, Shen G, Ma L, Shord S, Goldberg KB, Farrell AT, McKee AE, Pazdur R.

Oncologist. 2017 Nov;22(11):1347-1353. doi: 10.1634/theoncologist.2017-0229. Epub 2017 Sep 13.

7.

Haplotype phasing of whole human genomes using bead-based barcode partitioning in a single tube.

Zhang F, Christiansen L, Thomas J, Pokholok D, Jackson R, Morrell N, Zhao Y, Wiley M, Welch E, Jaeger E, Granat A, Norberg SJ, Halpern A, C Rogert M, Ronaghi M, Shendure J, Gormley N, Gunderson KL, Steemers FJ.

Nat Biotechnol. 2017 Sep;35(9):852-857. doi: 10.1038/nbt.3897. Epub 2017 Jun 26.

PMID:
28650462
8.

Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis.

Metz LM, Li DKB, Traboulsee AL, Duquette P, Eliasziw M, Cerchiaro G, Greenfield J, Riddehough A, Yeung M, Kremenchutzky M, Vorobeychik G, Freedman MS, Bhan V, Blevins G, Marriott JJ, Grand'Maison F, Lee L, Thibault M, Hill MD, Yong VW; Minocycline in MS Study Team.

N Engl J Med. 2017 Jun 1;376(22):2122-2133. doi: 10.1056/NEJMoa1608889.

9.

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.

Anderson KC, Auclair D, Kelloff GJ, Sigman CC, Avet-Loiseau H, Farrell AT, Gormley NJ, Kumar SK, Landgren O, Munshi NC, Cavo M, Davies FE, Di Bacco A, Dickey JS, Gutman SI, Higley HR, Hussein MA, Jessup JM, Kirsch IR, Little RF, Loberg RD, Lohr JG, Mukundan L, Omel JL, Pugh TJ, Reaman GH, Robbins MD, Sasser AK, Valente N, Zamagni E.

Clin Cancer Res. 2017 Aug 1;23(15):3980-3993. doi: 10.1158/1078-0432.CCR-16-2895. Epub 2017 Apr 20.

10.

Measurable residual disease testing in acute myeloid leukaemia.

Hourigan CS, Gale RP, Gormley NJ, Ossenkoppele GJ, Walter RB.

Leukemia. 2017 Jul;31(7):1482-1490. doi: 10.1038/leu.2017.113. Epub 2017 Apr 7. Review.

PMID:
28386105
11.

FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma.

Gormley NJ, Ko CW, Deisseroth A, Nie L, Kaminskas E, Kormanik N, Goldberg KB, Farrell AT, Pazdur R.

Clin Cancer Res. 2017 Nov 15;23(22):6759-6763. doi: 10.1158/1078-0432.CCR-16-2870. Epub 2017 Mar 1.

12.

Improved genome sequencing using an engineered transposase.

Kia A, Gloeckner C, Osothprarop T, Gormley N, Bomati E, Stephenson M, Goryshin I, He MM.

BMC Biotechnol. 2017 Jan 17;17(1):6. doi: 10.1186/s12896-016-0326-1.

13.
14.

Minimal Residual Disease as a Potential Surrogate End Point-Lingering Questions.

Gormley NJ, Farrell AT, Pazdur R.

JAMA Oncol. 2017 Jan 1;3(1):18-20. doi: 10.1001/jamaoncol.2016.3112. No abstract available.

PMID:
27632052
15.

Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma.

Gormley NJ, Turley DM, Dickey JS, Farrell AT, Reaman GH, Stafford E, Carrington L, Marti GE.

Cytometry B Clin Cytom. 2016 Jan;90(1):73-80. doi: 10.1002/cyto.b.21268. Epub 2015 Jul 25.

16.

NxTrim: optimized trimming of Illumina mate pair reads.

O'Connell J, Schulz-Trieglaff O, Carlson E, Hims MM, Gormley NA, Cox AJ.

Bioinformatics. 2015 Jun 15;31(12):2035-7. doi: 10.1093/bioinformatics/btv057. Epub 2015 Feb 5.

PMID:
25661542
17.

Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium.

Landgren O, Gormley N, Turley D, Owen RG, Rawstron A, Paiva B, Barnett D, Arroz M, Wallace P, Durie B, Yuan C, Dogan A, Stetler-Stevenson M, Marti GE.

Am J Hematol. 2014 Dec;89(12):1159-60. doi: 10.1002/ajh.23831. No abstract available.

18.

Recombinant human factor VIIa for alveolar hemorrhage following allogeneic stem cell transplantation.

Elinoff JM, Bagci U, Moriyama B, Dreiling JL, Foster B, Gormley NJ, Salit RB, Cai R, Sun J, Beri A, Reda DJ, Fakhrejahani F, Battiwalla M, Baird K, Cuellar-Rodriguez JM, Kang EM, Pavletic SZ, Fowler DH, John Barrett A, Lozier JN, Kleiner DE Jr, Mollura DJ, Childs RW, Suffredini AF.

Biol Blood Marrow Transplant. 2014 Jul;20(7):969-78. doi: 10.1016/j.bbmt.2014.03.015. Epub 2014 Mar 20.

19.

Clonality of HTLV-2 in natural infection.

Melamed A, Witkover AD, Laydon DJ, Brown R, Ladell K, Miners K, Rowan AG, Gormley N, Price DA, Taylor GP, Murphy EL, Bangham CR.

PLoS Pathog. 2014 Mar 13;10(3):e1004006. doi: 10.1371/journal.ppat.1004006. eCollection 2014 Mar.

20.

Rapid single-colony whole-genome sequencing of bacterial pathogens.

Köser CU, Fraser LJ, Ioannou A, Becq J, Ellington MJ, Holden MT, Reuter S, Török ME, Bentley SD, Parkhill J, Gormley NA, Smith GP, Peacock SJ.

J Antimicrob Chemother. 2014 May;69(5):1275-81. doi: 10.1093/jac/dkt494. Epub 2013 Dec 25.

Supplemental Content

Loading ...
Support Center